Fortrea (FTRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$17.70-4.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Fortrea is improving its profit margins with adjusted EBITDA growing from $30.3M in 2025-Q3 to $47.0M in 2026-Q1. The company guides full-year 2026 adjusted EBITDA around $205M. Restructuring charges fell from $22.4M in 2025-Q4 to $6.7M in 2026-Q1, showing cost control progress.
Cash flow is weak with operating cash flow turning negative to $(17.0)M in 2026-Q1. Revenue is expected to decline slightly next year. The company remains loss-making and faces high risk with a PE above peers.
The price is about 16% above our fair value near $15, reflecting roughly flat revenue growth expected by analysts. Our fair value is below the Street median, indicating some optimism may be stretched.
Breaks if: Adjusted EBITDA falls below $190M in 2026-FY
Drive operational and financial excellence to increase adjusted EBITDA and expand margins.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
FTRE represents a speculative growth investment. The company is currently navigating a challenging environment with high risk while showing strong recent financial performance.
The market seems to have priced in a justified valuation, with a low expectations gap. FTRE trades at a premium compared to its peers, indicating that some growth potential is already anticipated.
Management is focused on stabilizing and growing revenue, improving adjusted EBITDA, and enhancing cash flow. Recent results show mixed progress, with revenue slightly declining but adjusted EBITDA and cash flow improving.
The thesis hinges on several factors, including management's ability to maintain revenue growth and improve margins. Additionally, sector performance and broader economic indicators, like job reports, will play a critical role in shaping future outcomes.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
Yes, our read has strengthened. The latest earnings beat supports this improvement. The company is stabilizing and growing revenue. It is also improving adjusted EBITDA and margin expansion. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA increased from $54.9 million in 2025-Q2 to $58.7 million in 2026-Q2, and for the first half of 2026 reached $105.7 million versus $85.2 million in first half 2025. Management's repeated emphasis on margin expansion aligns with improving adjusted EBITDA, indicating delivering progress on this priority.
“Focused on commercial execution, operational excellence and financial discipline as we continue our strategic journey toward sustainable growth and margin expansion.”
“Making advances in our strategic journey back to growth and margin expansion.”
“Beginning the new year on strong footing for our journey back to growth and margin expansion.”
Breaks if: Cash flow remains negative through 2026-FY
Improve operating cash flow and free cash flow through disciplined capital allocation and operational improvements.
Stated as a priority in 3 of last 3 quarters. Operating cash flow improved to $28.9 million in 2026-Q2 from a negative $17.0 million in 2026-Q1, with free cash flow positive at $19.9 million in 2026-Q2. Management's focus on disciplined capital allocation and balance sheet strength is reflected in improving cash flow metrics, showing delivering progress.
“Cash provided by operations of $28.9 million and free cash flow of $19.9 million.”
“Net cash used for operating activities was $(17.0) million and free cash flow was $(25.0) million.”
“Operating cash flow was $113.5 million and free cash flow was $88.3 million for full year 2025.”
Breaks if: Restructuring charges rise above $10M in 2026-Q1
Continue restructuring and cost management initiatives to reduce overcapacity and align resources.
Stated as a priority in 3 of last 3 quarters. Restructuring charges have declined from $22.4 million in 2025-Q4 to $2.7 million in 2026-Q2, indicating progress in managing workforce and restructuring costs. Management continues to emphasize this priority, and the trajectory shows delivering cost reduction in this area.
“Restructuring and other charges of $2.7 million in the quarter related to elimination of redundant positions and realignment.”
“Restructuring and other charges of $6.7 million related to workforce reductions and realignment.”
“Restructuring and other charges of $22.4 million related to elimination of redundant positions and organizational realignment.”
Breaks if: Revenue falls below $2.55B in 2026-FY
In the next 1 to 3 years, FTRE's performance will depend on its execution and external market conditions. Not investment advice.